UBS analyst Michael Yee has reaffirmed a Buy rating for Merck & Company (MRK) and set a price target of $175.00. Yee, who covers the Healthcare sector, has an average return of 1.1% and a 44.75% success rate on recommended stocks, according to TipRanks. His focus includes companies like Vertex Pharmaceuticals, Amgen, and Bristol-Myers Squibb.
Merck & Company also received a Buy rating from Bank of America Securities’s Jason Gerberry today. However, Cantor Fitzgerald took a more cautious stance, assigning a Hold rating to MRK in a report issued yesterday. Despite the mixed analyst ratings, Merck reported strong quarterly revenue of $16.61 billion for the period ending June 30, though it faced a GAAP net loss of $1.34 billion. This contrasts with the previous year’s revenue of $15.8 billion and a net profit of $4.43 billion.
Insider sentiment for Merck & Company appears negative, with 53 insiders showing increased selling activity over the past quarter. Most recently, Jennifer Zachary, the EVP & GC of MRK, sold 80,315 shares in August 2026 for a total of $10,718,036.75. This trend suggests a lack of confidence among corporate insiders regarding the stock’s near-term prospects.